Note de episod
In today’s episode, we sit down with Jacob, co-founder & CEO of NewLimit, a company that has raised $247M to push the frontier of aging science from epigenetic reprogramming to AI-driven drug discovery.
We dive deep into how NewLimit plans to restore youthful function in human cells, what’s actually possible with aging reversal, how AI accelerates drug discovery, why GLP-1s changed the game, and whether there’s a real chance that none of this works.
If you're curious about biology, longevity, AI in drug discovery, or what it takes to build a $1.5B+ biotech startup from scratch this episode…
Site: share.transistor.fm

